The Orange Pill Podcast

 
A 2025 randomized, double-blind, placebo-controlled trial explored whether a combination of Polypodium leucotomos, Red Orange extract, and vitamins could help strengthen the skin’s natural defenses against UVB exposure.
After eight weeks, participants showed a 23.8% increase in UV tolerance and a 46.2% reduction in UVB-induced redness, without significantly affecting tanning.
In Episode 136 of the Orange Pill Podcast, we explore the emerging science of oral photoprotection and why the future of sun protection may involve supporting the skin from both the outside and the inside.

What does it really cost to make GRAS notification mandatory?
The FDA’s proposed GRAS overhaul promises greater transparency, but the headline numbers may not tell the whole story. Beyond the administrative cost of filing a notification are potentially much larger expenses tied to toxicology, exposure assessments, expert review, regulatory support, and delays.
In Episode 135 of the Orange Pill Podcast, we unpack the economics behind the proposal, the difference between paying for the “envelope” and the scientific “dossier,” and why smaller ingredient innovators could feel the impact most.
The question isn’t whether transparency has value—it’s what that transparency will ultimately cost.

What if one of the world’s oldest, and most expensive spices could have a measurable impact on the everyday “gray zone” of mental health?
In Episode 134 of the Orange Pill Podcast, we explore a 2025 randomized controlled trial examining a standardized saffron extract in 202 adults experiencing subclinical depressive symptoms.
We break down five findings from the study and explore a bigger question for the nutraceutical industry: Could standardized botanicals play a greater role in supporting people who fall somewhere between feeling well and having a diagnosed mental health condition?

A proposed FDA rule could fundamentally change how new food ingredients enter the U.S. marketplace.
In Episode 133 of the Orange Pill Podcast, we unpack the FDA's proposal to move from voluntary to mandatory GRAS notifications, and explore what this shift could mean for food innovation, regulatory transparency, consumer safety, and the future of ingredient development.

Millions of people struggle with constipation, yet many still rely on laxatives that simply force the digestive system into action.
In Episode 132 of the Orange Pill Podcast, we explore why fructooligosaccharides (FOS), a clinically studied prebiotic, may represent a smarter approach to digestive health.
Learn how FOS nourishes beneficial gut bacteria, promotes natural bowel function, and supports long-term digestive wellness through the power of the microbiome.

Clinical trials are essential, but choosing the wrong dose, population, or endpoint can derail a study before it begins.
In Episode 131 of the Orange Pill Podcast, we introduce the KGK Design Intelligence Lab and explore how in silico dietary modeling can simulate health outcomes across virtual populations before the first participant is enrolled.
By combining randomized clinical trial data, NHANES population insights, and advanced statistical modeling, researchers can design smarter, more targeted, and better-informed human studies.

Can one of the world's most researched plant compounds actually improve athletic performance, or have we been asking the wrong question?
In this episode of the Orange Pill Podcast, we explore the science behind quercetin, the flavonoid once hailed as an "exercise mimetic" after remarkable animal studies.
Discover why early human trials largely disappointed, how new delivery technologies are changing the conversation, and why quercetin's greatest benefit may not be improving race-day performance, but helping athletes recover faster and train harder.

For decades, America's food innovation system has relied on the self-GRAS pathway, allowing companies to determine the safety of new ingredients without mandatory FDA notification.
That system may be about to change.
In this episode of the Orange Pill Podcast, we explore the proposed federal legislation that could fundamentally reshape how food ingredients reach the marketplace, and what it means for manufacturers, regulators, and consumers alike.

Why do two people eating the exact same meal have completely different metabolic responses?
In this episode of the Orange Pill Podcast, we explore the groundbreaking PREDICT study, the largest personalized nutrition study of its kind, which challenges decades of conventional dietary advice.
From your gut microbiome and meal timing to machine learning and metabolic fingerprints, discover why the future of nutrition may be far more personal than we've ever imagined.

A new Utah law is expanding the definition of "specialized products", and the implications could extend well beyond cannabinoids and nicotine.
In this episode of the Orange Pill Podcast, we unpack H.B. 385, the legislation introducing new licensing, testing, and reporting requirements for products with psychoactive, sedative, or analgesic properties.
From melatonin and botanicals to retailer liability and product transparency, we explore what this law could mean for the future of supplement regulation in the United States.